Trial Profile

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel
Indications Ischaemic stroke
Focus Therapeutic Use
Acronyms CSPS.com
Sponsors Otsuka Pharmaceutical

Most Recent Events

03 Feb 2023 Results of subanalysis comparing the safety and effectiveness of DAPT and single antiplatelet therapy in preventing recurrence in chronic lacunar stroke, published in the Stroke
11 Feb 2022 Results of subgroup analysis investigating the effects of extracranial or intracranial arterial stenosis on the benefit of cilostazol presented at the International Stroke Conference 2022
24 Jan 2022 Results of post-hoc analysis published in the Neurology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com